Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Celularity Inc. (CELUW)

    Price:

    0.05 USD

    ( + 0.01 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    CELUW
    Name
    Celularity Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    0.048
    Market Cap
    1.147M
    Enterprise value
    73.828M
    Currency
    USD
    Ceo
    Robert Joseph Hariri
    Full Time Employees
    120
    Ipo Date
    2021-07-19
    City
    Florham Park
    Address
    170 Park Avenue

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    61.406B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    99.053B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.254B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -1.463
    P/S
    1.674
    P/B
    9.586
    Debt/Equity
    3.285
    EV/FCF
    -18.144
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    2.196
    Earnings yield
    -0.683
    Debt/assets
    0.219
    FUNDAMENTALS
    Net debt/ebidta
    -0.647
    Interest coverage
    -6.124
    Research And Developement To Revenue
    0.321
    Intangile to total assets
    0.125
    Capex to operating cash flow
    -0.025
    Capex to revenue
    0.003
    Capex to depreciation
    0.020
    Return on tangible assets
    -0.499
    Debt to market cap
    0.320
    Piotroski Score
    5.000
    FUNDAMENTALS
    PEG
    0.020
    P/CF
    -13.235
    P/FCF
    -13.832
    RoA %
    -43.632
    RoIC %
    -47.073
    Gross Profit Margin %
    83.598
    Quick Ratio
    0.282
    Current Ratio
    0.383
    Net Profit Margin %
    -106.772
    Net-Net
    -4.932
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.294
    Revenue per share
    2.426
    Net income per share
    -2.590
    Operating cash flow per share
    -0.286
    Free cash flow per share
    -0.294
    Cash per share
    0.033
    Book value per share
    0.395
    Tangible book value per share
    -0.347
    Shareholders equity per share
    0.395
    Interest debt per share
    1.579
    TECHNICAL
    52 weeks high
    0.060
    52 weeks low
    0.048
    Current trading session High
    0.048
    Current trading session Low
    0.048
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.478
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.121
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.463
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.589
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.187
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.966
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.877
    DESCRIPTION

    Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

    NEWS